title: The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report.
abstract: We report on a 61-year-old postmenopausal female with schizophrenia included in a raloxifene vs. placebo clinical trial and monitored during a 12-month period including a 3-month withdrawal period (6-9 months) without treatment. The patient was treated with raloxifene 60 mg/day adjuvant to antipsychotic medication for 6 months, medication was then withdrawn for 3 months and was reintroduced due to a worsening of symptoms. We assessed the patient with PANSS and other neuropsychological tests. The patient improved in psychopathology and cognitive level in some aspects related to executive functions. During 3 months without the drug, the patient's condition deteriorated. When the drug was reintroduced, improvements were again observed. Raloxifene may be useful as an adjuvant treatment for psychopathological symptoms and some cognitive aspects in women with chronic schizophrenia.
authors.affiliation: Parc Sanitari Sant Joan de Déu, C/Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain. mehuerta@pssjd.org.|Department of Psychiatry and Legal Medicine, Autonomous University of Barcelona, Bellaterra, Barcelona, Spain. mehuerta@pssjd.org.|Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain. mehuerta@pssjd.org.
authors.forename: Elena
authors.initials: E
authors.lastname: Huerta-Ramos
authors.affiliation: Parc Sanitari Sant Joan de Déu, C/Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.|Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain.
authors.forename: Susana
authors.initials: S
authors.lastname: Ochoa
authors.affiliation: Parc Sanitari Sant Joan de Déu, C/Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.|Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Roca
authors.affiliation: Parc Sanitari Sant Joan de Déu, C/Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Miquel
authors.affiliation: Parc Sanitari Sant Joan de Déu, C/Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.|Instituto de Salud Carlos III, Centro de Investigación en Red de Salud Mental (CIBERSAM), Madrid, Spain.
authors.forename: Judith
authors.initials: J
authors.lastname: Usall
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000175:diagnosis; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000523:psychology*; D011569:Psychiatric Status Rating Scales; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride